Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Namandje BumpusDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 06/18 | 06/22 | 3,963 sh | $3.18 | $12,602.34 | −3.0% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 06/05 | 06/05 | 40,000 sh | $3.62 | $144,800 | −4.3% |
Najat KhanCEO and President | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 06/05 | 06/05 | 23,588 sh | $3.58 | $84,445.04 | −1.1% |
Namandje BumpusDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 06/03 | 06/04 | 4,386 sh | $3.54 | $15,526.44 | −9.2% |
Blake BorgesonDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 06/02 | 06/04 | 30,000 sh | $3.68 | $110,400 | −0.5% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 05/22 | 05/27 | 40,000 sh | $3.08 | $123,200 | −4.3% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 05/07 | 05/08 | 40,000 sh | $3.37 | $134,800 | −4.1% |
Blake BorgesonDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 05/05 | 05/07 | 30,000 sh | $3.52 | $105,600 | −0.5% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 04/22 | 04/24 | 40,000 sh | $3.61 | $144,400 | −4.2% |
Blake BorgesonDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 04/07 | 04/08 | 30,000 sh | $3.10 | $93,000 | −0.5% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 04/07 | 04/08 | 40,000 sh | $3.10 | $124,000 | −4.2% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 03/23 | 03/25 | 40,000 sh | $3.25 | $130,000 | −4.2% |
Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 03/17 | 03/18 | 7,956 sh | $3.39 | $26,970.84 | −0.7% | |
Najat KhanCEO and President | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 03/09 | 03/11 | 28,298 sh | $3.35 | $94,798.3 | −1.2% |
Blake BorgesonDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 03/03 | 03/04 | 170,000 sh | $3.46 | $588,200 | −2.6% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 02/19 | 02/19 | 40,000 sh | $3.46 | $138,400 | −4.2% |
Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 02/18 | 02/19 | 13,426 sh | $3.08 | $41,352.08 | −1.1% | |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 02/04 | 02/06 | 40,000 sh | $4.12 | $164,800 | −4.2% |
Blake BorgesonDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 02/03 | 02/06 | 220,000 sh | $4.20 | $924,000 | −3.3% |
Gibson ChristopherDirector | Recursion PharmaceuticalsRXRX | Open-market sale10b5-1 plan | 01/20 | 01/22 | 40,000 sh | $4.47 | $178,800 | −4.2% |